RecruitingPhase IIEN originalLiver cancer

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This study will test the hypothesis that a novel combination of three drugs (sorafenib, sonidegib, and irinotecan), in conjunction with individually optimized doses, can be safely administered and lead to improved clinical outcomes in patients with hepatocellular carcinoma compared to standard of care. The main objective of this study is to establish safe dose ranges for the coadministration of sorafenib, sonidegib, and irinotecan in patients with hepatocellular carcinoma. Furthermore, we will collect data to inform the application of an artificial intelligence/computational approach to individual dosing of combination chemotherapy. Individualization of dosing will be achieved by using Phenotypic Personalized Medicine (PPM) to maximize treatment efficacy in patients with hepatocellular carcinoma, while minimizing toxicity. Drug efficacy will be assessed by measuring plasma circulating tumor DNA (ctDNA). Toxicity will be assessed by quantitating organ injury and patient tolerability. Recommended dosing for future studies will be based on the totality of the data.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Wiek 18 lat lub więcej
  • Potwierdzony zaawansowany rak wątroby (badaniem lub obrazowaniem)
  • Nie kwalifikujesz się do operacji lub masz nawrót choroby po poprzednich zabiegach
  • Ogólny stan zdrowia oceniany w skali 0-2 (możliwość codziennych czynności)
  • Dobra funkcja wątroby (klasa Child-Pugh A)
  • Oczekiwana długość życia co najmniej 12 tygodni
  • Wyniki badań krwi w normie lub blisko normy (liczba płytek, hemoglobina, białko, funkcja nerek i wątroby)
  • Zgoda na zastosowanie antykoncepcji przez co najmniej 20 miesięcy po leczeniu

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Maximum age
99 Years
Last updated (source)
July 14, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (1)

University of Florida

Gainesville, United States

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.